Valence 로고
인기
로그인

관심목록에 추가

HUTCHMED (China) Limited

NasdaqGS: HCM · 실시간 가격 · USD
12.64
+0.08 (0.64%)
종가 기준: Aug 18, 2026, 3:59 PM

HUTCHMED (China) Limited (HCM) Stock Price, Analysis & Data

0.64%
매수호가9.08
시가총액2.2B
매출 (ttm)549.12M
순이익 (ttm)17.88M
베타0.44
EPS (ttm)0.1
P/E (ttm)126.4
선행 P/E51.84
P/B (ttm)1.74
P/S (ttm)4.00
Earnings DateJul 30, 2017
매도호가16.17
거래량284,700
평균 거래량 (20일)57,191
시가12.60
전일 종가12.56
일중 범위12.48 - 12.76
52주 범위9.77 - 18.30
애널리스트Buy
목표주가18.75 (48.34%)
배당n/a
배당락일n/a

HCM 소개

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-C...

[더 보기]
산업 Drug Manufacturers - Specialty & Generic
섹터 Healthcare
IPO 일자 Mar 16, 2016
직원 수 1,790
상장 거래소 NasdaqGS
티커 HCM
웹사이트 https://www.hutch-med.com
전체 기업 정보

재무 실적

2025년 HUTCHMED (China)의 매출은 548.51M로, 전년 630.2M 대비 -12.96% 감소했습니다. 순이익은 456.91M로, 1,111.03% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 14명의 투자의견을 종합하면 HCM 주식의 평균 등급은 "Buy"입니다. 12개월 목표주가는 18.75로, 최근 주가 대비 48.34% 상승 여력입니다.

주가 전망

어닝 서프라이즈

HUTCHMED (China)가 Mar 2, 2022에 분기 실적을 발표했습니다:
  • 매출 n/a 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.03 예상치 상회 0.10, 및 0.00% 전년 대비 성장.

    • 다음 실적 발표

    HUTCHMED (China) Limited의 실적 발표 예정일은 Jul 30, 2017, 장 마감 후입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1일 전 · Proactive

    HUTCHMED shares rise as lung cancer drug trial hits key targets

    Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung ...

    news image

    2주 전 · GuruFocus.com

    HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ...

    HUTCHMED (China) Ltd (HCM) reports robust China product sales and global expansion, while advancing its novel ATTC pipeline and maintaining a profitable outlook.

    news image

    2주 전 · MarketBeat

    HUTCHMED H1 Earnings Call Highlights

    HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported r...

    news image

    2개월 전 · Insider Monkey

    Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

    We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Mo...

    news image

    3개월 전 · MarketBeat

    HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference

    HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at th...

    2 페이지 중 1